Literature DB >> 26203071

Biotinidase deficiency mimicking neuromyelitis optica: Initially exhibiting symptoms in adulthood.

Laure Bottin1, Sabine Prud'hon1, Stéphanie Guey1, Claire Giannesini1, Barry Wolf2, Kirit Pindolia2, Bruno Stankoff3.   

Abstract

BACKGROUND: Children with untreated biotinidase deficiency can experience variable symptoms depending on their age of presentation. Older children and adolescents can exhibit predominant neurological deficits including para- or tetraparesis and vision loss.
METHODS: We report the first case of delayed-onset biotinidase deficiency in a young adult.
RESULTS: A 22-year-old man presented with a disabling extensive myelopathy and bilateral optic neuropathy which mimicked the findings of a (seronegative) neuromyelitis optica. Imaging investigations were characterized by an MRI T2 hyper-intensity involving the spinal cord, the optic nerves, the fornix and the mammillar bodies, together with an increased (18)F-FDG uptake on positron emission tomography. He was ultimately shown to have profound biotinidase deficiency due to a novel missense mutation and was partly improved by oral biotin therapy.
CONCLUSION: This individual exemplifies the need to include biotinidase deficiency in the differential diagnosis of patients with extensive myelopathy and/or bilateral optic neuropathy and argues for newborn screening for the disorder.
© The Author(s), 2015.

Entities:  

Keywords:  Biotinidase deficiency; myelopathy; neuromyelitis optica; newborn screening; scotoma

Mesh:

Year:  2015        PMID: 26203071     DOI: 10.1177/1352458515596457

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  15 in total

Review 1.  Clinical utility gene card for: Biotinidase deficiency-update 2015.

Authors:  Sébastien Küry; Vincent Ramaekers; Stéphane Bézieau; Barry Wolf
Journal:  Eur J Hum Genet       Date:  2015-11-18       Impact factor: 4.246

2.  "Think metabolic" in adults with diagnostic challenges: Biotinidase deficiency as a paradigm disorder.

Authors:  Barry Wolf
Journal:  Neurol Clin Pract       Date:  2017-12

3.  Irreversibility of Symptoms with Biotin Therapy in an Adult with Profound Biotinidase Deficiency.

Authors:  Patrick Ferreira; Alicia Chan; Barry Wolf
Journal:  JIMD Rep       Date:  2017-02-21

4.  Adult-Onset Biotinidase Deficiency Induces Acutely Progressing Leukoencephalopathy.

Authors:  Goichi Beck; Daisuke Hirozawa; Keiichiro Honma; Kousuke Baba; Hisae Sumi; Eiichi Morii; Shigeo Murayama; Hideki Mochizuki
Journal:  Neurol Clin Pract       Date:  2021-06

Review 5.  Inherited metabolic diseases mimicking hereditary spastic paraplegia (HSP): a chance for treatment.

Authors:  Hélio A G Teive; Carlos Henrique F Camargo; Eduardo R Pereira; Léo Coutinho; Renato P Munhoz
Journal:  Neurogenetics       Date:  2022-04-09       Impact factor: 3.017

6.  Laboratory diagnosis of biotinidase deficiency, 2017 update: a technical standard and guideline of the American College of Medical Genetics and Genomics.

Authors:  Erin T Strovel; Tina M Cowan; Anna I Scott; Barry Wolf
Journal:  Genet Med       Date:  2017-07-05       Impact factor: 8.822

7.  Outcomes of oral biotin treatment in patients with biotinidase deficiency - Twenty years follow-up.

Authors:  Edyta Szymańska; Małgorzata Średzińska; Agnieszka Ługowska; Magdalena Pajdowska; Dariusz Rokicki; Anna Tylki-Szymańska
Journal:  Mol Genet Metab Rep       Date:  2015-10-06

8.  Any individual with multiple sclerosis who markedly improves neurologically with high-doses of biotin should be evaluated for biotinidase deficiency.

Authors:  Barry Wolf
Journal:  Mult Scler J Exp Transl Clin       Date:  2020-04-29

Review 9.  Pediatric Neuromyelitis Optica Spectrum Disorders.

Authors:  Grace Y Gombolay; Tanuja Chitnis
Journal:  Curr Treat Options Neurol       Date:  2018-05-02       Impact factor: 3.972

Review 10.  Pediatric NMOSD: A Review and Position Statement on Approach to Work-Up and Diagnosis.

Authors:  Silvia Tenembaum; E Ann Yeh
Journal:  Front Pediatr       Date:  2020-06-25       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.